Download Alzheimer's Disease Market Forecast Brochure

Survey
yes no Was this document useful for you?
   Thank you for your participation!

* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project

Document related concepts

Market analysis wikipedia , lookup

Marketing ethics wikipedia , lookup

Channel coordination wikipedia , lookup

Foreign market entry modes wikipedia , lookup

Market penetration wikipedia , lookup

Transcript
Brochure
More information from http://www.researchandmarkets.com/reports/1504829/
Alzheimer's Disease Market Forecast
Description:
Valued at almost $6bn in the seven major markets in 2011 (US, Japan, France, Germany, Italy, Spain, and the
UK), the Alzheimer’s disease drug market is forecast to experience double-digit growth to 2020. The catalysts
for this include an aging population, earlier and improved diagnosis, and the introduction of
immunotherapies that will be prescribed in addition to existing treatments.
Features and benefits
- Access Datamonitor’s patient-based Alzheimer’s disease market forecast in the seven major markets, with
transparent methodology and clear assumptions.
- Evaluate a highly granular forecast with sales value and volume projections to 2020 at the country, class,
product, and indication level.
- Understand Alzheimer’s disease market dynamics and which factors will lead to commercial success.
- Review the products Datamonitor forecasts to launch over the next ten years, and how each subsequent
launch will shape the market.
Highlights
- The Alzheimer’s disease market in the seven major markets is set to more than double over the next 10
years, from $5.8bn in 2011 to $14.5bn in 2020. The catalysts for this growth include an increasingly elderly
population, earlier and improved diagnosis, and the introduction of immunotherapies.
- Pfizer/Eisai’s Aricept (donepezil) is set to remain the highest-selling brand in 2011 with
Forest/Lundbeck/Merz’s Namenda (memantine) close behind. However, the two drugs are following differing
growth trajectories: Namenda’s sales will continue to rise while Aricept’s revenues are being severely eroded
by generic competition.
- Beta-amyloid immunotherapies such as bapineuzumab, solanezumab, and Gammagard have the potential
to grow the market by $7.6bn. Datamonitor forecasts that around 600,000 patients with mild cognitive
impairment or mild to moderate Alzheimer’s disease will receive immunotherapies annually by 2020 in the
seven major markets.
Your key questions answered
- What degree of commercial success does Datamonitor forecast for key pipeline drugs?
- What will the overall Alzheimer’s disease market dynamics be over the next 10 years?
- How will sales of the major drug classes in Alzheimer’s disease evolve during the forecast period?
- Which of the seven major markets provides the greatest opportunity for growth?
- Which Alzheimer’s disease indications are the most lucrative?
Contents:
OVERVIEW
Summary
Introduction
Features and benefits
Research and analysis highlights
Key questions answered
Forecasting methodology
Volume and value forecast methodology
Price and compliance assumptions
Disclaimer
Ordering:
Order Online - http://www.researchandmarkets.com/reports/1504829/
Order by Fax - using the form below
Order by Post - print the order form below and send to
Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Page 1 of 2
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from
USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit
http://www.researchandmarkets.com/contact/
Order Information
Please verify that the product information is correct and select the format(s) you require.
Product Name:
Alzheimer's Disease Market Forecast
Web Address:
http://www.researchandmarkets.com/reports/1504829/
Office Code:
SCHL3FA7
Product Formats
Please select the product formats and quantity you require:
Quantity
Electronic (PDF) Single User:
USD 11400
Electronic (PDF) Enterprisewide:
USD 28500
Contact Information
Please enter all the information below in BLOCK CAPITALS
Title:
First Name:
Mr
Mrs
Dr
Miss
Last Name:
Email Address: *
Job Title:
Organisation:
Address:
City:
Postal / Zip Code:
Country:
Phone Number:
Fax Number:
* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Ms
Prof
Page 2 of 2
Payment Information
Please indicate the payment method you would like to use by selecting the appropriate box.
Pay by credit card:
You will receive an email with a link to a secure webpage to enter your
credit card details.
Pay by check:
Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.
Pay by wire transfer:
Please transfer funds to:
Account number
833 130 83
Sort code
98-53-30
Swift code
ULSBIE2D
IBAN number
IE78ULSB98533083313083
Bank Address
Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.
If you have a Marketing Code please enter it below:
Marketing Code:
Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at
http://www.researchandmarkets.com/info/terms.asp
Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World